tbuckley/cabot-search huggingface dataset:
Definition of the accelerated phase of chronic myelogenous leukemia.
Authors: H M Kantarjian, M Talpaz
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.1.180 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3422090 Definition of the accelerated phase of chronic myelogenous leukemia. H M KantarjianxH M KantarjianSearch for articles by this author , M TalpazxM TalpazSearch for articles by this author https://doi.org/10.1200/JCO.1988.6.1.180 First Page PDF © 1988 by American Society of Clinical Oncology
Feasibility of Dose-Dense Paclitaxel/Carboplatin Therapy in Elderly Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer
Authors: S. Bun, M. Yunokawa, M. Kodaira, J. Hashimoto, H. Yamamoto, C. Shimizu, Y. Fujiwara, Y. Makino, H. Iwase, K. Tamura, Y. Hayashi
Journal: Annals of Oncology (2014)
OP0096-HPR Medication Adherence in Rheumatoid Arthritis and Psoriatic Arthritis Patients: Table 1.
Authors: L. Barbosa, I. Cordeiro, A. Cordeiro, M.J. Santos, J.C. da Silva
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic systemic illnesses that demand lifelong treatment. Adhesion to therapy is fundamental to achieve adequate disease control. <h3>Objectives</h3> We aimed to assess adherence to chronic therapy in RA and PsA patients and to identify reasons of non-adherence. <h3>Methods</h3> An anonymous written self-reported questionnaire was applied to consecutive RA and PsA patients followed-up in our Day Care Rheumatology Unit. Demographic and clinical characteristics were evaluated as well as chronic medication prescribed. Medication adherence was assessed using a qualitative 4-point scale. Patients were deemed adherent when stated that drug was always taken as prescribed. Reasons for non-adherence were collected. Presence and intensity of side effects was also investigated. Patients were asked to indicate one drug that they would like to stop and to specify the reasons for their choice. Variables independently associated with non-adherence where assessed by logistic regression analyses. <h3>Results</h3> One hundred and five participants were included: 83 females, 85 RA patients, with a mean age of 55±13 years and mean disease duration of 13±8 years. Drugs with lowest self-reported adherence were calcium supplements (58.3%, n=60) followed by hydroxychloroquine (62.5%, n=16) and the drugs with highest level of adherence were subcutaneous biologics (90.9% of patients, n=44) and leflunomide (85.7%, n=7). Forgetfulness was most often the perceived reason for non-adherence (67.8% of patients, n=59), followed by fear/presence of side effects (11.9% each). The drugs most frequently appointed for discontinuation were methotrexate (50% of patients, n=64) and glucocorticoids (23.4%), mainly due to fear of (69.4%, n=62) or presence of adverse events (27.4%). Methotrexate side effects most often indicated were nausea (25.3% of patients, n=87) and hair loss (18.4%). Younger age was associated with non-adherence to methotrexate and calcium supplement use (table 1). <h3>Conclusions</h3> We identified forgetfulness and fear/presence of side effects as the main barriers to adherence. Consequently, we are committed to improve doctor-nurse/patient communication, assuring a clear and individual explanation of the importance of maintaining adherence and possible side effects of each therapy at the beginning of treatment and at each consultation. Proactive management of side effects, even if mild, is encouraged. Additionally, health care professionals should encourage and implement group education sessions where rheumatic diseases and treatments are discussed with patients and where there will be the opportunity to clarify doubts and improve coping strategies. <h3>Disclosure of Interest</h3> None declared
AB0733 Localized Scleroderma: Extra-Cutaneous Manifestations and Association with Other Autoimmune Diseases in a Series of 78 Cases
Authors: W.A. Sifuentes Giraldo, C. Sobrino Grande, L. Villalobos Sánchez, A. Alia Jiménez, E. de Las Heras Alonso, C. de la Puente Bujidos, M.L. Gámir Gámir
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Extreme variation in provider nutritional practices in the NICU leads to poor growth of premature infants. Standardization of current feeding practices through quality improvement may improve growth trajectory and developmental outcomes. <h3>Objectives</h3> Increase the mean delta Z score for weight (difference in z-score between birth weight and discharge weight) from −1.8 to −1 within 6 months and sustain for 1 year, for neonates with birth weight (BW) &lt;1500 grams, admitted within the 1 st week of life. <h3>Methods</h3> A multidisciplinary team evaluated nutrition practices for VLBW infants and key drivers were determined (figure 1). Re-education around our current feeding protocol and intolerance decision aid, sharing growth information during rounds using an in-house assessment tool (figure 2), increased accessibility to breast pump rentals, standardization of lactation consultation ordering, and development of an infographic to assist mothers in choosing breast milk over formula (figure 3) were interventions tested using the IHI Model for Improvement. Mean delta Z score for weight (primary outcome measure) and number of lactation consultation orders per week (process measure) were recorded and analyzed. <h3>Results</h3> Mean delta weight Z-score increased from −1.8 to −1.08 (figure 4) following the implementation of all of the noted interventions with centerline shift that has lasted for 8 months (40% improvement). Mean number of lactation consults ordered per week increased from 1 to 4. <h3>Conclusions</h3> Reducing nutrition practice variation shows marked improvements in infant nutrition status. We continue to test other interventions with the hope of further decreasing growth failure.
AB0146 Rebamipide Inhibits IL-1β-Induced Proliferation of rheumatoid Arthritis Synovial Fibroblasts Through the Phosphor-Jun N-Terminal Kinase (P-JNK) Pathway
Authors: W.S. Lee, Y.J. Choi, Y.-H. Cheon, M.-J. Hong, C.-H. Lee, M.S. Lee, S.-I. Lee, W.-H. Yoo
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rebamipide is an antiulcer drug that protects gastric epithelial cells, improves gastric defense mechanisms by increasing gastric mucus, increases prostaglandin production, and reduces free oxygen radicals. Interestingly, recent research has demonstrated that rebamipide acts as an oxygen radical scavenger and also exhibits anti-inflammatory activity. <h3>Objectives</h3> We determined the effects of rebamipide on the production of proinflammatory mediators, including MMPs, COX-2, and PGE2, and signaling pathway produced by rheumatoid arthritis synovial fibroblasts (RASFs) and the proliferation of these cells after stimulation with IL-1β. <h3>Methods</h3> The proliferation of RASFs was evaluated with CCK-8 reagent in the presence of IL-1β with/without rebamipide. The expression of MMPs, tissue inhibitor of metalloproteinase-1 (TIMP-1), COXs, members of the intracellular mitogen-activated protein kinase (MAPK) signaling pathway, including p-ERK, p-p38, p-JNK, and nuclear factor-kappaB (NF-κB), and the production of PGE2 were examined by western blotting or semi-quantitative RT-PCR and ELISA. <h3>Results</h3> Rebamipide inhibited IL-1β–induced RASF proliferation. The inhibitory effects of rebamipide were significantly enhanced in a dose-dependent manner. IL-1β enhanced the expression of MMP-1 and MMP-3, but not that of TIMP-1, in RASFs, as per the results of mRNA expression. The expression of MMP-1 and MMP-3 were significantly inhibited by treatment with rebamipide at 48 h. IL-1β phosphorylated the intracellular NK-κB and MAPKs including ERK, p-38, and JNK. Rebamipide significantly inhibited IL-1β–induced NF-κB and intracellular JNK activation, but it did not inhibit the activation of ERK and p-38. <h3>Conclusions</h3> To the best of our knowledge, this is the first study to report that repamipide can inhibit the IL-1β-induced proliferation of RASFs via the inhibition of IL-1β-induced activation of NF-κB and phosphorylation of the JNK pathway. These findings suggest that rebamipide may be beneficial for the treatment of patients with RA. <h3>Disclosure of Interest</h3> None declared
Abdominal uptake of I-131 revealing a renal cyst.
Authors: BECHIR LETAIEF, SAMI BOUGHATTAS, MOHSEN GUEZGUEZ, HABIB HASSINE, HABIB ESSABBAH
Journal: Clinical Nuclear Medicine (2001)

LETAIEF, BECHIR M.D.; BOUGHATTAS, SAMI M.D.; GUEZGUEZ, MOHSEN M.D.; HASSINE, HABIB M.D.; ESSABBAH, HABIB M.D. Author Information
Combination Chemotherapy: Synergism between a Possible Folic Acid Antagonist and Ethionine on a “Solid” Tumor&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Daniel M. Shapiro, Ruth A. Fugmann
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Combination Chemotherapy: Synergism between a Possible Folic Acid Antagonist and Ethionine on a “Solid” Tumor Get access Daniel M. Shapiro, Daniel M. Shapiro Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Ruth A. Fugmann Ruth A. Fugmann Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 2, February 1957, Pages 201–207, https://doi.org/10.1093/jnci/18.2.201 Published: 01 February 1957 Article history Received: 28 August 1956 Published: 01 February 1957
Stem Cell and T-Cell Gene Therapy Using SIN-Lentiviral Vector In Type 3 Familial Hemophagocytic Lymphohistiocytosis
Authors: Julie Rivière, Tayebeh Soheili, Els Verhoeyen, Anne Galy, Geneviève de Saint Basile, Alain Fischer, Isabelle Andre-Schmutz, Marina Cavazzana
Journal: Blood (2013)
Low spinophilin expression is associated with poor prognosis and cellular growth in human breast cancer
Authors: D. Schwarzenbacher, V. Stiegelbauer, A. Deutsch, A.L. Ress, A. Aigelsreiter, S. Schauer, A. Gerger, G. Höfler, B. Rinner, M. Pichler
Journal: Annals of Oncology (2015)
Alexithymia in medical patients referred to a consultation/liaison service
Authors: G R Smith
Journal: American Journal of Psychiatry (1983)

Seventy-three medically ill patients referred to a consultation/liaison service over a 4-month period were evaluated for alexithymia. Twenty-two (30%) of these patients had alexithymia. Age, race, and marital status were not associated with alexithymia scores. Patients in lower socioeconomic groups and men had significantly higher scores than their counterparts. The idea that alexithymia is prevalent in individuals with a diagnosis of a "psychosomatic disease" was not supported.
A multidisciplinary team approach to cancer care in a community based teaching hospital
Authors: N. J. Petrelli, S. Grubbs, K. Price, C. Cordrey, T. Kempista, D. Biggs, P. Grusenmeyer, P. Strusowski
Journal: Journal of Clinical Oncology (2004)

6102 Background: In June 2002 the Helen F. Graham Cancer Center (HFGCC) at Christiana Care Health Services (CCHS) opened its doors to establish the multi-disciplinary team approach for cancer care. This program was deemed necessary in view of the fact that the State of Delaware has the fourth highest cancer incidence and mortality rates in the United States. Methods: Disease site Multi-disciplinary Centers (MDC's) were established in Genitourinary, Head and Neck, Hepatobiliary -Pancreatic, Lymphoma, Neuro-Oncology, Thoracic/Esophageal, Colorectal, and Breast. A surgeon, medical and radiation oncologist was assigned to each of the MDC's. Physicians needed to meet certain performance expectations in order to participate in the MDC's. Support services consisting of psychology, nutrition, genetic counseling, social service, oncology nurse care manager, and a clinical trials research nurse were assigned to each of the MDC's. CCHS is an NCI funded Clinical Community Oncology Program. Results: In the first 7 months, June through December 2002, there were 921 patient visits in the MDC's at the HFGCC. In the second 7 months, January through July 2003, patient visits increased to 1,563. From 6/1/02 through 11/18/03 there were 309 patients placed on NCI Cooperative Group trials at CCHS . Of the 390 patients, there were 42 patients ( 13%) that were placed on NCI clinical trials as per their visit to the MDC's. This was 7% of the 580 patients seen in the MDC's from 6/1/03 through 11/18/03. The percentage of analytic cases ( first treatment or diagnosis at CCHS) accrued to clinical trials in 2001 and 2002 were 10.0% and 13.2% respectively. Patients saved on average 3 weeks of physician appointment time by visiting the HFGCC where they were seen by the surgeon, medical and radiation oncologist in one visit. Conclusions: The disease site multi-disciplinary team approach to cancer care decreased the time to patient care planning and treatment and has continued to be an additional mechanism for patient accrual to NCI clinical trials. No significant financial relationships to disclose.
Abstract 2090: GLI3 repressor levels determine Hedgehog pathway activity and predict response to Smoothened antagonist in acute myeloid leukemia
Authors: Parvesh Chaudhry, Mohan Singh, Tim Triche, Aparna Jorapur, Parkash S. Gill, Akil Merchant
Journal: Cancer Research (2015)

Abstract The Hedgehog (Hh) signaling pathway is activated in most hematological and solid cancers and is a promising target for therapeutic development. Deletions in the receptor Patched (PTCH) or activating mutations in the upstream positive regulator Smoothened (SMO) have been reported in a few cancers such as basal cell carcinoma and medulloblastoma, but are largely absent in most tumor types; therefore, the mechanism of pathway activation in most cancers remains unknown. In normal tissues, Hh pathway activation via PTCH/SMO causes an increase in the downstream activating transcription factor GLI1 and a decrease in the transcriptional repressor GLI3R. We confirm that the Hh pathway is active in acute myeloid leukemia (AML) and is required for cell survival, however, this activity is largely independent of the upstream activator SMO. Using siRNA knock down of GLI1, GLI3 and SMO in AML cell lines, Gli3 conditional knock out mice, and primary AML samples, we are able to show that loss of the GLI3R repressor function is sufficient to activate Hh target gene expression independent of ligand binding, and GLI3R levels correlate inversely with GLI1 levels. Importantly, we show that GLI3R is required for the therapeutic effect of SMO antagonists in AML samples and restoration of GLI3R restores sensitivity to SMO antagonists in AML cell lines. Epigenetic and gene expression analysis of the TCGA AML data set reveals that the GLI3 expression is silenced in most AML patient samples. We demonstrate in vitro and in patients that treatment with hypomethylating agents restores GLI3R levels and sensitivity to SMO antagonists in AML. In a transgenic mouse model of myeloproliferative disease (vav-Jak2V617F, gift of Joe Zhao, OUHSC) effective treatment with SMO antagonists are associated with increases in GLI3R but no changes in GLI1. Finally we show that GLI3R can directly repress expression of AKT and in vivo responses to SMO antagonists are correlated with changes in AKT expression, independent of GLI1 levels. In summary, this study provides the first evidence that GLI3R plays an essential role in SMO independent Hh signaling in AML, and suggests that GLI3R could serve as a potential biomarker for patient selection in SMO antagonist clinical trials. Furthermore, these data provide important mechanistic data to support rational combinations of hypomethylating agents with SMO antagonists in clinical trials. Citation Format: Parvesh Chaudhry, Mohan Singh, Tim Triche, Aparna Jorapur, Parkash S. Gill, Akil Merchant. GLI3 repressor levels determine Hedgehog pathway activity and predict response to Smoothened antagonist in acute myeloid leukemia. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2090. doi:10.1158/1538-7445.AM2015-2090
Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania
Authors: A S Brown, A G Mallinger, L C Renbaum
Journal: American Journal of Psychiatry (1993)

Membrane phospholipids were measured in platelets of seven medication-free patients in the manic phase of bipolar affective disorder and seven healthy comparison subjects. The relative percentage of platelet membrane phosphatidylinositol-4,5-bisphosphate was significantly higher in the manic patients than in the comparison subjects. These results are consistent with an enhanced neuronal second messenger response after 5-hydroxytryptamine receptor stimulation followed by neurotransmitter release.
Hepaticogastrostomy by Echo-Endoscopy as a Palliative Treatment in a Patient with Metastatic Biliary Obstruction
Authors: M. Giovannini, M. Dotti, E. Bories, V. Moutardier, C. Pesenti, C. Danisi, J. Delpero
Journal: Endoscopy (2003)

A palliative hepaticogastrostomy was performed under endoscopic ultrasound guidance in a patient with inoperable hepatic hilar obstruction, creating an anastomosis between the dilated left hepatic duct and the stomach, to relieve symptoms of cholangitis and to allow biliary drainage. This therapeutic procedure was used as an alternative method of drainage of the biliary tree because endoscopic retrograde cholangiopancreatography was not possible and because the percutaneous metallic stent which had been inserted earlier had become occluded (probably by tumor overgrowth). It was a two-step procedure. In the first step a hepatic duct was punctured through the gastric wall with placement of a plastic stent, which created a fistula between them. In a second step a covered, metallic, self-expandable stent was substituted for the plastic stent to maintain the anastomosis and to improve patency over the medium term. The patient's fever was relieved and the bilirubin level fell; the patient remained asymptomatic at the five-months-follow-up.
ANTIGENICITY OF RAT COLLAGEN
Authors: Sidney Rothbard, Robert F. Watson
Journal: The Journal of Experimental Medicine (1962)

Antibody to rat collagen, prepared in rabbits and injected into the circulation of normal or adjuvant-prepared rats, becomes fixed to its antigen and can then be identified in tissue sections under ultraviolet light by its fluorescence after application of fluorescein-conjugated anti-rabbit globulin. In heart, lung, liver, spleen, adrenal, kidney, jejunum, lymph node, thymus, joint synovia, peripheral nerve, aorta, skeletal muscle, eye, and brain, the antibody was found at all sites where collagen and reticulin are normally present, but except for the kidneys of the adjuvant-prepared rats, no pathological abnormalities were demonstrated. It was not found within cells. Specific fluorescence was absent from tissues of rats injected with normal rabbit serum or rabbit anti-fish collagen serum or rabbit anti-rat collagen serum after absorption with rat collagen, but was present when the anti-rat collagen serum had been absorbed with fish collagen. The reaction could be blocked by pretreatment of sections with unlabeled anti-rabbit globulin and did not occur with heterologous labeled anti-duck globulin. After serial treatment in vitro with homologous antibody to collagen and the conjugated anti-rabbit globulin, purified reconstituted collagen fibers showed the same fluorescence as fibers in the tissues; no fluorescence of the fibers occurred when heterologous antibody to collagen was applied. These findings indicate that the antibody to rat collagen is directed toward an antigen present in both collagen and reticulin.
Accelerated Development of Transplanted Mammary Tumors in Mice Pretreated With the Methanol Extraction Residue of BCG and Prevention of Acceleration by Concomitant Specific Immunization2
Authors: Diane M. Jacobs, Margaret L. Kripke
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Accelerated Development of Transplanted Mammary Tumors in Mice Pretreated With the Methanol Extraction Residue of BCG and Prevention of Acceleration by Concomitant Specific Immunization Get access Diane M. Jacobs, Diane M. Jacobs Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret L. Kripke Margaret L. Kripke Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 1, January 1974, Pages 219–224, https://doi.org/10.1093/jnci/52.1.219 Published: 01 January 1974 Article history Received: 17 July 1973 Accepted: 24 September 1973 Published: 01 January 1974
PTH-048 Quality of life and ileo-anal pouch function after restorative proctocolectomy: a 20-year experience
Authors: N Randhawa, A Barlow
Journal: Gut (2015)

<h3>Introduction</h3> Ileo-anal pouch formation is the preferred option for restoring continuity in patients post proctocolectomy. The aim of this study was to assess the long-term functional outcome of the W-pouch and its impact on the patient’s quality of life. <h3>Method</h3> A consecutive series of 62 patients who had undergone restorative proctocolectomy with W ileo-anal pouch formation between 1995 and 2014 were sent questionnaires to assess the long-term functional outcome of the pouch and its effect on their quality of life (QOL). Patients had been operated on by a single surgeon using an identical technique. Patients were divided in to two groups: patients who have been living with a pouch for 10 years or more or those who have had a pouch for less than 10 years. The differences between both groups were analysed using the Mann-Whitney U test. <h3>Results</h3> 38 out of 62 patients (61%) responded to the postal questionnaires. They were similar to the overall group in terms of gender, age, length of stay and indication for surgery. Overall, 27 patients (71%) reported &lt;5 bowel movements (BM)/day and nine (24%) reported no BM at night. 37 patients (97%) reported good or excellent continence. Only one patient had soiling either during day or night. 30 patients (79%) were able to defer defecation for &gt;1 h. Anti-diarrhoea medication was needed daily by 15 patients (39%) or occasionally by seven patients (18%). A possible episode of pouchitis was reported by 13 patients (34%). 35 patients (92%) preferred a pouch to an ileostomy. There was no difference in functional outcomes reported by those who had a pouch &lt;10 years (20 patients) compared with those with a pouch &gt;10 years (18 patients). QOL measures were also similar across both groups. However, anxiety levels were found to be higher in those with a pouch &gt;10 years (p = 0.02). <h3>Conclusion</h3> Patients with ileo-anal pouch anastomosis have a good quality of life and long-term pouch outcome, which does not deteriorate with time. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Perrin, A. Quality of life after ileo-anal pouch formation: patient perceptions. <i>Br J Nurs</i>. 2012;26(21):16 Andersson T, Lunde OC, Johnson E <i>et al</i>. Long-term functional outcome and quality of life after restorative proctocolectomy with ileo-anal anastomosis for colitis.<i>Colorectal Dis</i>. 2011;4:431–7